We are Traded On
NASDAQ: ELAB
2020
Formation of Elevai Labs Inc.
Elevai Labs was incorporated in Delaware, establishing itself as a physician-dispensed skincare company, focused on modernizing aesthetic skincare with innovative stem cell-derived Elevai Exosomes™ products.
2023
Q4
Elevai Labs, Inc. Nasdaq Initial Public Offering (IPO)
On November 20, 2023, Elevai Labs priced its IPO, raising $6 million through the sale of 1.5 million shares of common stock at $4.00 per share. The company began trading on the Nasdaq Capital Market under the ticker symbol "ELAB."
2024
Q2
Initiation of Restructuring with the Launch of two wholly owned subsidiaries Elevai Biosciences, Inc. and Elevai Skincare, Inc.
Elevai Biosciences focused on biopharmaceutical innovations, including obesity-targeting assets EL-22 and EL-32. Elevai Skincare became dedicated to commercializing Elevai's exosome skincare technologies, with an emphasis on scaling and increasing market penetration in the medical skincare industry.
Q4
Parent company Elevai Labs Inc. leadership transition and corporate name change to PMGC Holdings Inc. Announces Pricing of $8.0 Million Public Offering
2025
Q1
The sale of Elevai Skincare to Carmell Corporation
Sold Elevai Skincare to Carmell Corporation, strengthening PMGC's balance sheet, maximizing immediate financial benefit while securing future upside through structured royalties and milestone payments.Note: PMGC Holdings (formerly known as Elevai Labs)
Expands Investment & M&A Efforts, Actively Seeking Acquisitions
Q2
Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company